Seagen Inc

-0.05 (-0.04%)
4:00:23 PM EDT: $144.96 +0.24 (+0.17%)
Equity Investments, Other Pre-Announcement

Seattle Genetics And Merck Announce Two Strategic Oncology Collaborations

Published: 09/14/2020 11:38 GMT
Seagen Inc (SGEN) - Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations.
Seattle Genetics Inc - Merck to Acquire $1 Billion Equity Stake in Seattle Genetics Common Stock.
Seattle Genetics Inc - Companies to Co-develop and Co-commercialize Seattle Genetics' Antibody-drug Conjugate Ladiratuzumab Vedotin Globally.
Seattle Genetics Inc - Under Terms of Agreement, Seattle Genetics Will Receive a $600 Million Upfront Payment.
Seattle Genetics Inc - Separately Has Granted Merck an Exclusive License to Commercialize Tukysa(®) (tucatinib).
Seattle Genetics Inc - Seattle Genetics is Eligible for Progress-dependent Milestone Payments of Up to $2.6 Billion for Ladiratuzumab Vedotin.
Seattle Genetics - Granted Merck License to Commercialize Tukysa in Asia, Middle East & Latin America & Other Regions Outside of U.S., Canada & Europe.
Seattle Genetics Inc - Merck Will Make a $1.0 Billion Equity Investment in 5.0 Million Shares of Seattle Genetics Common Stock at a Price of $200 per Share.
Seattle Genetics Inc - Will Receive $125 Million From Merck As Upfront Payment and Eligible for Progress-dependent Milestones of Up to $65 Million for Tukysa.
Seattle Genetics Inc - Financial Impact of These Collaborations is Not Included in Seattle Genetics' 2020 Guidance.
Seattle Genetics Inc - Would Receive Tiered Royalties on Sales of Tukysa in Merck's Territory.
Seattle Genetics - Under Ladiratuzumab Vedotin Collaboration, Co is Eligible to Receive Up to $4.2 Billion.